5月22日,宜明昂科-B(01541)午前涨幅持续扩大,股价上涨17.07%,报9.60港元,成交额7874.53万港元。华创证券表示,IMM0306治疗系统性红斑狼疮(SLE)预计2025年中读出全球首个巨噬细胞疗法临床数据,并于下半年递交美国IND。此外,国元国际指出,公司与InstilBio签订协议,授权其在大中华区外开发IMM2510和IMM27M,可获最高达21亿美元里程碑付款及特许权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.